Barriers to Treat-to-Target in Rheumatoid Arthritis A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation. https://t.co/CMEd62BfU0 https://t.co/YHQ408No4S

Economic, Personal Burden of RA: Maybe Not So Bad? Data from a major federal survey indicate that people with RA don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found. https://t.co/ZFw7KZ0Wsb https://t.co/bO02YbzWvb

NEJM Clinical Images: Coup de Sabre (linear scleroderma) 70-year-old woman with a history of hypothyroidism presented to the dermatology clinic with a 1-year history of progressive indentation and darkening of the skin of her forehead https://t.co/RiVNQiy5MM https://t.co/pxVEqBIUWP

CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM). https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip

Gout Forecast: 70% Increase by 2050 The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2021 has forecasted prevalence of gout to increase by 70% by 2050. https://t.co/7OSQXSBtUc https://t.co/p9hkO5xzAa

PROs: Their Proper Place https://t.co/gYjrRcqLy4 https://t.co/QJ9DYp8JuV

UK Biobank 11+ yr study of 5728 incident gout pts - light alcohol decreased in gout incidence among females (HR 0.78). Light red wine also reduced gout risk, whereas beer or cider, champagne or white wine, and spirits increased the gout risk at any dose. https://t.co/nP8vObFsOH https://t.co/DuXQMyeaE3

Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja

Lead with Lupus (8.2.2024) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv - leading with lupus because everyone wants to know about lupus! https://t.co/kzoijNGyfd https://t.co/S2llbb0pMO

FDA issued draft guidance, which, if implemented, would remove requirement for a switching study for demonstrating biosimilar interchangeability. Citing research showing no additional safety concerns if pts switched from reference biologics to biosimilars https://t.co/MBvI4yxajW https://t.co/sEE654E2rl

N Zealand Rheum Assn audit of 355 new seropositive pts referred, saw 65% starting DMARDs w/in 6 wks. DMARD starts were linked rurality & the # of rheumatologists. If there was 1 Rheum FTE/100,000 population, 80% were on DMARDs <=6wks https://t.co/8OvniRQt1I https://t.co/TsgegOJ9ZG

US News & World Report Top US Med Schools for Research Baylor Case Western Emory Hofstra Mayo Northwestern Ohio State UCLA UCSD UCSF U Cincinnati U Colorado U Pittsburgh UTSW Vanderbilt Yale https://t.co/VSEnBxWUF2 https://t.co/bGCBCD8npX